Patronus Biotech Receives Ethical Approval to Begin First-in-Human Phase 1 Trial of Three Multi-Stage Vaccines Against Malaria in Australia

Contributed by: PR Newswire

Tags

Patronus-Biotech

More Like This

ILiAD Biotechnologies Announces Lancet Microbe Publication of BPZE1 Phase 2b Clinical Results in Human Challenge Model

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease

Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting